China Medical System Holdings (HK:0867) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
China Medical System Holdings announced the acceptance of their New Drug Application for ruxolitinib phosphate cream, aimed at treating vitiligo, by China’s National Medical Products Administration. The cream showed significant efficacy in a Chinese Real-World Study, outperforming target values with mild to moderate adverse events. This product has potential to help the millions suffering from this chronic autoimmune skin condition in China and has already been made available in Hainan’s Pilot Zone and approved in Macau.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.